Close Menu

NEW YORK (GenomeWeb) – Having just pulled down $8.5 million in funding from a $21.5 million Series B round closed in early 2012, Miragen Therapeutics is gearing up to file investigational new drug applications for up to two of its proprietary microRNA drug candidates before the end of this year.

In doing so, the company is laying the groundwork for clinical studies that it hopes will generate proof-of-concept data around its therapeutic approach in order to woo investors for a planned initial public offering next year, Miragen President and CEO Bill Marshall told GenomeWeb.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

As the Canadian election season heats up, neither major party has really paid much attention to science, according to Nature News.

BBC News says the uncertainty over Brexit is affecting science funding in the UK.

A new app purports to tell users "how gay" they are by looking at their DNA, but experts tell Futurism that the app is bunk.

In Nature this week: human and great ape cerebral organoids reveal aspects of brain development unique to humans, and more.